Thalassemia clinical trials at UC Cancer
2 research studies open to eligible people
A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease
open to eligible people ages 12-65
This clinical trial is a Phase 2 study that will evaluate the safety and clinical activity of etavopivat in patients with thalassemia or sickle cell disease and test how well etavopivat works to lower the number of red blood cell transfusions required and increase hemoglobin.
at UCLA UCSF
Red Blood Cell - IMProving trAnsfusions for Chronically Transfused Recipients
open to all eligible people
Red Blood Cell - IMProving trAnsfusions for Chronically Transfused recipients (RBC-IMPACT) is an observational cohort study to assess donor, component, and recipient factors that contribute to RBC efficacy in chronically and episodically transfused patients. The objective of the study is to determine how specific genetic and non-genetic factors in donors and recipients may impact RBC survival after transfusion - in short, what factors on both the donor and recipient side may improve the efficacy of the transfusion.